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Background: Nucleolin is a protein over-expressed on the surface of tumor and endothelial cells. Recent studies
have underlined the involvement of cell surface nucleolin in tumor growth and angiogenesis. This cell surface
molecule serves as a receptor for various ligands implicated in pathophysiological processes such as growth factors,
cell adhesion molecules like integrins, selectins or laminin-1, lipoproteins and viruses (HIV and coxsackie B). HB-19 is
a synthetic multimeric pseudopeptide that binds cell surface expressed nucleolin and inhibits both tumor growth
and angiogenesis.
Methodology/principal findings: In the present work, we further investigated the biological actions of
pseudopeptide HB-19 on HUVECs. In a previous work, we have shown that HB-19 inhibits the in vivo angiogenesis on
the chicken embryo CAM assay. We now provide evidence that HB-19 inhibits the in vitro adhesion, migration and
proliferation of HUVECs without inducing their apoptosis. The above biological actions seem to be regulated by SRC,
ERK1/2, AKT and FAK kinases as we found that HB-19 inhibits their activation in HUVECs. Matrix metalloproteinases
(MMPs) play crucial roles in tumor growth and angiogenesis, so we investigated the effect of HB-19 on the expression
of MMP-2 and we found that HB-19 downregulates MMP-2 in HUVECs. Finally, down regulation of nucleolin using
siRNA confirmed the implication of nucleolin in the biological actions of these peptides.
Conclusions/significance: Taken together, these results indicate that HB-19 could constitute an interesting tool for
tumor therapy strategy, targeting cell surface nucleolin.Introduction
Nucleolin is a nucleolar protein ubiquitously expressed in
exponentially growing eukaryotic cells. It was first
described in 1973 as a protein involved in ribosome bio-
genesis and also in DNA and RNA metabolism [1]. More
recently, nucleolin was shown to shuttle between cyto-
plasm and cell surface. In the cytoplasm, it provides a post-
transcriptional regulation of mRNA and at the cell surface
it serves as a low affinity receptor for several ligands such
as growth factors [2,3]. Cell surface nucleolin was first
described in hepatocarcinoma cells, suggesting that this
molecule is involved in the growth of tumor cells [4].
Since this report, a growing body of evidence has pointed
out the involvement of cell-surface expressed nucleolin in
cell proliferation, and more specifically in tumor cell
growth and angiogenesis. Surface nucleolin expression is
constantly enhanced in various tumor cell lines and* Correspondence: katsopan@upatras.gr
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reproduction in any medium, provided the oractivated endothelial cells [2,5,6] and this expression is
constantly induced in these cells [7]. The expression of
nucleolin is enhanced on the surface of endothelial cells
upon stimulation with the vascular endothelial growth fac-
tor (VEGF) [8]. The functional blockade or downregulation
of surface nucleolin in endothelial cells inhibits their
migration and prevents capillary-tubule formation [8]. Fur-
thermore, several molecules related to cell proliferation or
differentiation, have been reported as ligands for cell sur-
face nucleolin. Among these molecules are the hepatocyte
growth factor (HGF), the heparin affin regulatory peptide
(HARP), midkine (MK), the epithelial growth factor recep-
tor (ErbB) and endostatin, which all play a significant role
in tumor development and angiogenesis processes [9-12].
In addition, molecules involved in mechanisms regulating
pericellular proteolysis, cell-surface adhesion and mitoge-
nesis (such as urokinase) bind and are co-internalized with
surface nucleolin [13,14]. Other surface nucleolin binding
proteins such as laminin-1, factor J, L- and P-selectins are
involved in cell differentiation and regulate cell adhesion,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[15-19]. Cell surface nucleolin, as a novel target for
anticancer therapy, was validated by using several
molecules such as endostatin, the aptamer AS1411,
the acharan sulfate and the homing tumor peptide
F3 [20-22]. Furthermore, targeting nucleolin using a
specific antibody causes activated endothelial cells
apoptosis by decreasing the anti-apoptotic bcl2
mRNA in tumor vasculature [23].
In a previous study, we have reported that the nucleolin
binding multivalent pseudopeptide HB-19 suppressed
both tumor growth and angiogenesis [24]. HB-19 binds
the RGG domain located in the C-terminal part of nucleo-
lin and leads to its internalization [9,24]. In vitro, HB-19
reduces tumor cell growth in soft agar assay in several car-
cinoma cell lines and impairs endothelial cells prolifera-
tion, migration and differentiation induced by VEGF [24].
These activities in both tumor and activated endothelial
cells lead to tumor growth inhibition in breast carcinoma
MDA-MB 231 and human melanoma MDA-MB 435
xenografts in athymic nude mice, without displaying any
toxicity in normal tissues [24].
In this study, we have further investigated the anti-
angiogenic activities and the mechanism of action of HB-
19 on human umbilical vein endothelial cells (HUVECs).Materials and methods
Ethics statement
For this study, we have obtained ethics approval from
the ethics committee of University of Patras.Endothelial cell culture
Human umbilical vein endothelial cells (HUVECs)
were isolated from the umbilical cord vein by col-
lagenase digestion as previously described [25] and
used at passages 2–4. The cells were grown as
monolayers in medium M199 supplemented with
15% fetal bovine serum (FBS), 150 μg/ml of endothe-
lial cell growth supplement, 5 U/ml heparin sodium,
100 U/ml penicillin-streptomycin and 50 μg/ml gen-
tamycin. Cultures were maintained at 37°C, 5% CO2
and 100% humidity.Cell proliferation assay
An equal number of cultured HUVECs in medium
containing 15% FBS were left to adhere for 20 h in a
cell culture microplate. They were then treated with
various HB-19 concentrations and were allowed to
proliferate for 3 days. The cell number was estimated
by the crystal violet assay. Data are the mean ± SEM
of at least three independent experiments.Boyden chamber assay
Migration assays were performed as previously described
[26] in a 24-well microchemotaxis chamber (Costar,
Avon, France), using untreated polycarbonate mem-
branes with 8 μm pores. HUVECs were harvested and
resuspended at a concentration of 105 cells/0.1 ml in the
corresponding medium containing 0.25% bovine serum
albumin (BSA) and HB-19. The bottom chamber was
filled with 0.6 ml of the corresponding medium contai-
ning 0.25% BSA. The upper chamber was loaded with
105 cells and incubated for 4 h at 37°C. After completion
of the incubation, filters were fixed, non-migrated cells
were scrapped off the upper side of the filter, and filters
were stained with crystal violet. The number of migrated
cells was quantified by counting the entire area of the fil-
ter using a grid and an Optech microscope at a 20x
magnification.
In vitro endothelial cell wound healing assay
HUVECs were cultured in 6-well plates 2×105 cells/well as
confluent monolayers. The monolayers were wounded in
a line across the well with a 200 μl standard pipette tip,
washed twice with PBS to remove cell debris and incu-
bated with increasing concentrations of HB-19 for 48 h.
The area of the initial wound was photographed using a
charge-coupled device camera connected to an inverted
microscope (Axiovert 35; Zeiss, Thornwood, NY). The
wound healing effect was calculated in comparison with
the area of the initial wound.Western blot analysis
Cells were starved for 4 h and then incubated with various
concentrations of HB-19 for 15 min. Cells were subse-
quently washed twice with PBS and lysed in 250 μl 2×
SDS loading buffer under reducing conditions. Proteins
were separated by SDS-PAGE and transferred to an
Immobilon-P membrane for 3 h in 48 mM Tris pH 8.3, 39
mM glycine, 0.037% SDS, and 20% methanol. The mem-
brane was blocked in TBS containing 5% non-fat milk and
0.1% Tween 20 for 1 h at 37°C. Membranes were incu-
bated with primary antibody overnight at 4°C under con-
tinuous agitation, washed with PBS-Tween and incubated
with the appropriate secondary antibody coupled to horse-
radish peroxidase. Protein bands were detected using the
ChemiLucent Detection System Kit (Chemicon Inter-
national Inc., CA) according to the manufacturer’s instruc-
tions. Where indicated, blots were stripped in buffer
containing 0.5 mM Tris HCl pH 6.8, 2% SDS, 100 mM 2-
mercaptoethanol for 30 min at 56°C and re probed. A
quantitative estimation of band size and intensity was per-
formed through analysis of digital images using the Ima-
gePC image analysis software (Scion Corporation,
Frederick, MD).
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Secreted metalloproteinases were detected and characte-
rized by zymography. Conditioned media were obtained
after an 8 h incubation of cells in serum-free media
and then were loaded onto 10% SDS-PAGE gels that
had been co-polymerized with 1 mg/ml gelatin. Electro-
phoresis was carried out under non-reducing conditions
at 100 V for 2 h at 4°C. Gels were washed once for 60
min in 2.5% Triton X-100 to remove SDS and incu-
bated in zymogen activation buffer (50 mM Tris–HCl
pH 7.6, 10 mM CaCl2, 0.2M NaCl) for 24 h at 37°C.
Gels were stained with 0.5% Coomassie blue in 30%
methanol/10% acetic acid for 30 min at room
temperature and de-stained in 30% methanol/10% acetic
acid three times for 15 min. The presence of metallo-
proteinases was indicated by an unstained (due to pro-
teolysis) zone in the substrate. Both active forms and
pro-enzymes are revealed by this technique, since
exposure of pro-MMPs to SDS during SDS-PAGE leads
to activation without proteolytic cleavage. The relative
amounts of MMPs were quantified by NIH Image Ana-
lysis software. The normalization was based on the
number of cells of each well (using the crystal violet
method).Annexin V binding staining
The analysis of annexin V binding was carried out
with an Annexin V-FITC Detection Kit I (PharMingen,
San Diego, CA) according to the manufacturer’s instruc-
tions. An equal number of cultured HUVECs in medium
containing 15% FBS were left to adhere for 20 h in a cell
culture microplate. They were then treated with various
HB-19 concentrations and collected after 24 h, washed
twice with cold PBS, centrifuged at 200g for 5 min and
resuspended in binding buffer at a concentration of 106
cells per ml. 100 μl of the solution were transferred to a
5ml culture tube and 5 μl of annexin V-FITC and 5 μl of PI
were added. Cells were gently vortexed and incubated for
15 min at room temperature in the dark. Finally, 400 μl of
binding buffer were added to each tube, and samples were
analyzed by FACScan flow cytometer (Becton Dickinson).
For each sample, 10,000 ungated events were acquired.
PI (−)/annexin (+) cells represent early apoptotic
populations and PI (+)/annexin (+) cells represent
late apoptotic populations.Crystal violet assay
Adherent cells were fixed with methanol and stained
with 0.5% crystal violet in 20% methanol for 20 min.
After gentle rinsing with water, the retained dye was
extracted with 30% acetic acid, and the absorbance
was measured at 595 nm.Reverse transcriptase-polymerase chain reaction (RT-PCR)
for nucleolin, MMP2, and GAPDH
Total RNA was extracted using the Nucleospin RNA II
kit (Macherey-Nagel, Germany) according to the manu-
facturer’s instructions. The integrity of isolated RNA was
examined by electrophoresis on a 1% agarose gel con-
taining 0.5 mg/ml ethidium bromide. Specific primers
were as follows:
Nucleolin,
500- TGCCAAGAAGACAGTTACACCA −300 and
500- AGGAACAACTTTTGCAGCTTTC - 300;
MMP2,





The RT-PCR reactions were performed in a single step
with 250 ng of total RNA, using the Qiagen RT-PCR sys-
tem. The RT-PCR products were subjected to electro-
phoresis on 1% agarose gel containing 0.5 mg/ml
ethidium bromide, digitally photographed, and quanti-
fied using image analysis software (Scion Image PC,
Scion Corporation, Frederick, MD).
SiRNA transfection
RNA oligonucleotide primers were obtained from Ambion
Inc and the Lipofectamine RNAiMAX Transfection Agent
was obtained from Invitrogen. The following sequences
were used:
siRNA Nucleolin sense : 500-
GGAUAGUUACUGACCGGGA-300;
siRNA Nucleolin antisense: 500-
UCCCGGUCAGUAACUAUCC-300,
HUVECs were plated in 6 wells-plates and incubated
for 24 hours at 37°C. Cells were then transfected at a
final concentration of 10nM siRNA using Lipofectamine
RNAiMAX reagent (Invitrogen) according to the manu-
facturer's instructions.
Transfection efficiency was evaluated using Silencer
FAM Labelled GAPDH siRNA (Ambion). Negative con-
trol siRNAs from Ambion was also used.
Materials
Cell culture reagents were from BiochromKG (Seromed,
Germany). All other reagents were purchased from
Sigma-Aldrich. Monoclonal antibodies against pSRC
(Tyr416), pFAK (Tyr925), pAKT (Ser473), pERK1/2
(Thr202/Tyr204), total SRC, total ERK1/2 and were pur-
chased from Cell Signaling Technology. Polyclonal
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NCL (nucleolin) were purchased from Santa Cruz Bio-
technology, Inc.
Peptide synthesis
HB-19 was synthesized, as previously described, using
the solid phase peptide methodology [8].
Adhesion assay
24-well culture plates were coated with 1% v/v gelatin for
20 min at 370C. 5×104 resuspended cells incubated in
M199 medium with different concentrations of HB-19
for 30 min and then seeded. After a 30 min incubation
period, unattached cells were removed by shaking the
plates at 2,000 rpm for 10 sec, followed by three washes
with PBS. The attached cells number was estimated by
the crystal violet assay. Data are the mean ± SEM of at
least three independent experiments.
Statistical analysis
Comparisons of the mean values among groups were
performed by means of ANOVA and unpaired Student
t-test. Homogeneity of variances was tested by Levene’s
test. Each experiment included at least triplicate mea-
surements for each condition tested. All results are
expressed as mean ± SE. from at least three independent
experiments. Values of p less than 0.05 were accepted as
significant (*p < 0.05, **p < 0.01, ***p < 0.001).Figure 1 HB-19 inhibits the in vitro adhesion, proliferation, migration
19. An equal number of HUVECs were incubated with increasing concentra
period, adherent cells were measured by the crystal violet assay. Results are
from at least 3 independent experiments. (B) Inhibition of HUVECs prolifera
concentrations of HB-19. Cell proliferation was quantified by crystal violet s
mean values ± SE from at least 3 independent experiments. (C) Migration o
filters (8 μm pores) was filled with growth media containing 0.25% BSA. An
containing 0.25% BSA and increasing concentrations of HB-19, and transfer
filter pores, were fixed, stained and quantified by counting the entire area
are mean values ± SE from at least 3 independent experiments. (D) Conflu
wound in the presence of increasing concentrations of HB-19. 48 h later thResults
HB-19 inhibits adhesion, proliferation and migration of
HUVECs
The effect of HB-19 on the adhesion of HUVECs was
first investigated. As shown in Figure 1A, HB-19 signifi-
cantly inhibited the in vitro adhesion in a concentration-
dependent manner, reaching a maximal effect at a
concentration of 50 μΜ yielding 40% inhibition com-
pared to the control (Figure 1A). As cells will adhere if
left for more than 6 h, we investigated the effect of
HB-19 on the proliferation of HUVECs. HB-19 inhibited
cell proliferation in a concentration dependent manner,
having a maximal effect (41% inhibition relative to con-
trol) at a concentration of 50 μΜ (Figure 1B). We then
investigated the effect of HB-19 on HUVEC migration,
using Transwell assays. Similar to the effects on cell ad-
hesion and proliferation, HB-19 inhibited migration in a
concentration-dependent manner, with a maximal effect
(61% inhibition relative to control) observed at the con-
centration of 50 μM (Figure 1C). Furthermore, the effect
of HB-19 has been studied in wound-closure assay. As
shown in Figure 1D and Additional file 1:, HB-19 inhibits
HUVEC motility.
To confirm that HB-19 has a direct effect on adhesion
and migration and secondarily on proliferation without
affecting cell survival, a cytotoxic assay using HUVEC,
treated or not with various concentrations of HB-19, has
been performed. As shown in Figure 2, treatment ofand motility of HUVECs. (A) Inhibition of HUVECs adhesion by HB-
tions of HB-19 for 30 min before seeding. After a 45 min incubation
expressed as % change relative to control and are mean values ± SE
tion by HB-19. Cells were cultured for 3 days in presence of increasing
taining. Results are expressed as % change relative to control and are
f cells through Transwell filters. The lower compartment of Transwell
equal number of HUVECs was re suspended in growth medium
red into Transwell inserts. Cells that successfully migrated through the
of each filter. Results are expressed as % change relative to control and
ent cell monolayers were scratched and cells were left to heal the
e plates were photographed.
Figure 2 HB-19 does not induce apoptosis of HUVECs. (A and C), endothelial cells were incubated with increasing concentrations of HB-19
and 24 h later the number of apoptotic cells was measured by FACS analysis. (B), H2O2 was used as positive control.
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(as well as in 48 and 72 h, data not shown). Early apop-
totic cells, which are in the beginning of apoptosis, are
distinguished from already dead cells (late apoptosis).
The data indicated that treatment with HB-19 in various
concentrations for 24 h has no effect on the survival of
HUVECs and confirmed that HB-19 has a direct effect
on endothelial cells adhesion and migration and second-
arily on their proliferation.
HB-19 down-regulates MMP2 in HUVEC
We next studied the effect of HB-19 on the activation of
Matrix Metalloproteinases (MMPs) which are involved
in the degradation of extracellular matrix, a prerequisite
for cell migration. MMPs play a crucial role in angiogen-
esis, as they digest the ECM and facilitate the cell’s mi-
gration. MMP2 is expressed in endothelial as well as in
most cell types and is important for endothelial cell mi-
gration and vascular remodelling during angiogenesis
[27,28]. It also facilitates the migration of tumor cells
[29]. Matrix metalloproteinases (MMPs) are crucial in
angiogenesis as cells produce them so as to digest ECM
and facilitate their migration. Therefore, the effect of
HB-19 on the activation of MMPs was investigated. The
results showed that MMP2 activity was markedly
reduced by 1 μM of HB-19 (Figure 3A). We further
demonstrated that HB-19 suppressed the expression of
MMP2 mRNA as determined by RT-PCR (Figure 3B).
The results indicated that both enzyme activity and the
expression of MMP2 were inhibited by HB-19.
The results suggested that HB-19 and therefore nucleo-
lin might affect the expression of genes involved in pro-
teolytic activation.Inhibition of SRC, ERK1/2, FAK and AKT activation during
HB-19 stimulation of HUVECs in vitro
Several studies have indicated that the SRC, FAK, AKT
and MAPKs are involved in the signal transduction that
regulates angiogenesis [30,31]. Consequently, the effect
of HB-19 on the phosphorylation status of SRC, FAK,
AKT and ERK1/2 in HUVECs was investigated.
As shown in Figure 4A, HB-19 induced a decrease in
SRC phosphorylation within 15 min and in a concentra-
tion dependent manner, with a maximal effect (80%
inhibition relative to control) at a concentration of 10
μΜ. We found that FAK phosphorylation was decreased
15 min after incubation of HUVECs with HB-19 in a
concentration dependent manner. A significant decrease
is observed at a concentration of 1 μM yielding 51%
inhibition as compared to the control. Similarly, we
found that AKT phosphorylation was decreased 15 min
after incubation of HUVECs with HB-19 in a concentra-
tion dependent manner with a maximal effect (75% in-
hibition relative to control) at a concentration of 10 μΜ.
As shown in Figure 4D, ERK1/2 were also inactivated
after a15 min incubation with HB-19 in a concentration
dependent manner, reaching a maximal effect (66% in-
hibition relative to control) at a concentration of 10μΜ.
Taken together, these data indicate that HB-19 inhibits
the phosphorylation of all of these kinases in a dose-
dependent manner (Figure 4A, B, C and D). Results
showed that the anti-angiogenic action of HB-19 might
partly occur through a suppression of SRC, FAK, AKT
and ERK pathways, but further research is needed in
order to understand the mechanism of action of HB-19
and how it inhibits the activation of these signalling
pathways.
Figure 3 HB-19 down-regulates MMP2 in HUVECs. (A)
Endothelial cells were cultured in a minimal medium with increasing
concentrations of HB-19 and 8 h later the supernatants were
analyzed for MMP2 activity by zymography. Results are expressed as
% change relative to control and are mean values ± SE from at least
3 independent experiments. (B) Endothelial cells were incubated
with increasing concentrations of HB-19 and 24 h later total RNA
was extracted from the cells, RT-PCR reactions were performed using
specific primers for MMP2 or GAPDH mRNAs, the PCR products were
analyzed in agarose gels and quantified. Results are expressed as %
change relative to control and are mean values ± SE from at least 3
independent experiments.
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adhesion and proliferation of HUVECs and blocks the
inhibitory action of HB-19
In order to confirm that HB-19 exerts the previously
described biological actions mainly through nucleolin, as
well as the involvement of cell-surface nucleolin in these
effects, we transiently transfected HUVECs with a siRNA
targeting the mRNA of nucleolin. In parallel, HUVECs
were transiently transfected with a siRNA that does not
target any mRNA (negative control) (data not shown).
As shown in (Figure 5A and B), using specific siRNA
targeting nucleolin mRNA reduces the levels of mRNA
and protein up to 80% respectively.
As shown in (Figure 5C and D), NCL knockdown
blocked the inhibitory effect of HB-19 in HUVECs pro-
liferation and adhesion respectively. Moreover, the same
experiment shows that nucleolin is a crucial factor in
the proliferation and adhesion of HUVECs, since the
down-regulation of nucleolin expression by itself results
in the inhibition of proliferation and adhesion.
Down regulation of nucleolin expression inhibits SRC and
ERK1/2 activation in HUVECs and blocks the inhibitory
action of HB-19
Previous reports have shown that HB-19 interacts specif-
ically with cell surface nucleolin [32].
To confirm that HB-19 signalling takes place mainly
through nucleolin interaction, we tested the HB-19
effect on activation of SRC and ERK1/2 of transiently
transfected HUVECs with siRNA for nucleolin mRNA.
As shown in Figure 6A and B, the phosphorylation levels
of SRC and ERK1/2 are induced on transiently trans-
fected HUVECs compared with wild type cells, while
nucleolin knockdown blocked HB-19-induced SRC and
ERK1/2 inactivation.
Taken together, these results indicate that ΗΒ-19/
nucleolin interaction affects various signal transduction
pathways that reduce the phosphorylation levels of these
signal transduction molecules, and are involved in the
inhibition of cellular adhesion and proliferation.
Discussion
Several recent studies have described cell-surface nucleo-
lin as a molecule involved in tumor growth and angiogen-
esis [2,24,33]. Targeting surface nucleoproteins like
nucleolin with HB-19, is effective regarding the inhibition
of tumour cell proliferation and impairment of angioge-
nesis [24,33]. Therefore, functional blockade of surface
nucleoproteins seems to result in an inhibition that is not
due to a single growth factor implicated in carcinogenesis.
Previous studies of our group have shown the dual action
of HB-19 on tumour and endothelial cells, and have
pointed out surface nucleoproteins as an important antic-
ancer target [24]. The presence of nucleolin on the cell
Figure 4 HB-19 signalling down-regulates pSRC, pFAK, pAKT and pERK1/2. Western blot analysis of phosphorylated SRC, FAK, AKT and
ERK1/2, in cells stimulated by increasing concentrations of HB-19 for 15 minutes. The blots were stripped and re probed for total SRC, HSC70,
HSC70 and total ERK1/2 respectively. Results are expressed as % change relative to the control and are mean values ± SE from at least 3
independent experiments.
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plasmic nucleolin to the surface upon stimulation of cell
proliferation. Surface and cytoplasmic nucleolin are cha-
racterized by similar isoelectric points with pI values at
about 4.5, whereas nuclear nucleolin is composed of sev-
eral subspecies with pI values between 4 and 6 [3,32,34].
These observations lead to the suggestion that the expres-
sion of surface nucleolin should be differentially regulated
compared to its nuclear counterpart [7]. In support to this
assumption, it was shown that surface nucleolin is
N-glycosylated and that this N-glycosylation is required
for the expression and function of nucleolin at the cell
surface [35].
HB-19 binds the RGG domain at the C-terminal end
of nucleolin, which is also the site for binding of RNA
[36,37], rDNA [38], a subset of ribosomal proteins [39],
the urokinase-type plasminogen activator [14] and sev-
eral growth factors [9-12]. The irreversible binding of
HB-19 to this RGG domain could then prevent the
proper functioning of surface nucleolin, thereby exertingits antagonistic action. In view of the implications of this
in tumor growth and angiogenesis, as well as its capabi-
lity to bind pathogens and diverse range of ligands in-
cluding low density lipoproteins [1,2,5], it is plausible to
suggest that surface nucleoproteins could function as
scavenger receptors [40]. Nucleolin was also shown to
exist in a 500-kDa protein complex including several
other proteins that are implicated in cell signaling,
tumor cell adhesion, and other biological actions related
to tumorigenesis and angiogenesis. Targeting surface
nucleolin with HB-19 could change the organization of
this complex leading to antitumoral and antiangiogenic
effects. [33]
In this study, we sought to investigate the biological
actions of HB-19 in endothelial HUVECs. Our results
showed that HB-19 inhibits in vitro HUVECs adhesion,
migration and motility in a concentration dependent
manner (Figure 1A, C and D). If left for more than 6 h,
HUVECs will adhere and migrate even in the presence
of HB-19 (data not shown), therefore we investigated the
Figure 5 Effect of nucleolin (NCL) knockdown on HB-19 biological actions. Down-regulation of nucleolin (NCL) mRNA (A) and protein (B)
using specific siRNA targeting nucleolin mRNA. Effect of HB-19 (10μΜ) on proliferation (C) and adhesion (D) of HUVECs. The last two bars of each
diagram indicate HUVECs that were transiently transfected with siRNA targeting nucleolin (NCL). Results are expressed as % change relative to
control and are mean values ± SE from at least 3 independent experiments.
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that it is also inhibited, even if it is a secondary effect
(Figure 1B). The inhibitory effect of HB-19 on angiogen-
esis [24] as well as on HUVECs migration and motility
may be associated with down regulation of MMP2
[41,42]. We found that both enzyme activity and expres-
sion of MMP2 were inhibited by HB-19 (Figure 3). Fur-
thermore, we found that HB-19 treatment shows no
toxicity in HUVECs in vitro, as HB-19 didn’t induce apop-
tosis (Figure 2). HB-19 treatment is not toxic in various
experimental models in vitro as well as in vivo. The lack ofFigure 6 Effect of nucleolin (NCL) knockdown on HB-19-induced sign
ERK1/2 in HUVECs stimulated with 10 μM HB-19 for 15 minutes. The blots w
diagram indicate HUVECs that were transiently transfected with siRNA targ
and are mean values ± SE from at least 3 independent experiments.translocation of HB-19 to the nucleus probably accounts
for its lack of toxicity [24,33].
As mentioned above, several molecules that are involved
in tumor development and angiogenesis have been reported
to be ligands for cell-surface nucleolin. HB-19 binds the
C-terminal RGG domain of cell-surface expressed nucleolin
and blocks its function as a receptor or binding molecule
for various ligands [9,32,43,44]. Additionally, the binding of
an extracellular ligand to surface nucleolin has been
reported to be involved in the activation of signaling path-
ways by promoting Ca2+ entry into cells [45].al transduction. Western blot analysis of phosphorylated SRC and
ere stripped and re probed for HSC70. The last two bars of each
eting nucleolin. Results are expressed as % change relative to control
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affects and through which exerts its biological action, we
investigated the effect of this peptide on well known
angiogenic signalling pathways mediated by many of
these ligands of nucleolin.
We found that HB-19 inhibits the phosphorylation
levels of SRC, FAK, AKT, and ERK1/2 in a concentration-
dependent manner showing that the anti-angiogenic ac-
tion of HB-19 might partly occur through suppressing
SRC, FAK, AKT and ERK pathways.
Down regulating nucleolin, we found that the prolif-
eration and adhesion of HUVECs was inhibited, high-
lighting the importance of nucleolin in these biological
actions (Figure 5C and D). We studied the total effect of
nucleolin without distinguishing between surface and
nuclear nucleolin but we need to point out that the nu-
clear nucleolin has longer half life compared to the sur-
face one. To confirm that our siRNA was specific for
NCL, we examined the effect of siRNA on the expres-
sion of GAPDH mRNA as shown in Figure 5A and other
molecules such as tubulin (data not shown). The first
comprehensive review of nucleolin was published more
than 10 years ago and focused on the problem of riboso-
mal RNA transcription, maturation, and assembly [46],
principally because the expression of this major nucle-
olar phosphoprotein was directly correlated with riboso-
mal DNA (rDNA) transcription [46-50]. The focus of
nucleolin research has since widened to include chroma-
tin decondensation [51], cytoplasmic nucleolar transport
of ribosomal components and preribosomal particles
[47], and nucleogenesis [50]. In particular, nucleolin has
been shown to be a component of B cell-specific tran-
scription factor [52,53], an autoantigen [54,55], a DNA/
RNA helicase [56], DNA-dependent ATPase [57], and a
transcriptional repressor [58]. The protein therefore
appears to be involved in fundamental aspects of tran-
scriptional regulation, cell proliferation, and growth. Fur-
thermore, nucleolin is required for a correct mitosis,
controlled centrosome duplication [59] and plays a cru-
cial role in the cell cycle [60].
The inhibitory effect of HB-19 on cellular proliferation
and adhesion was almost completely blocked in the
transfected HUVECs compared to the wild type
(Figure 5C and D last two columns). Furthermore, the
phosphorylation levels of SRC and ERK1/2 are induced on
transiently transfected HUVECs compared with wild type
cells (Figure 6, first and third columns), while nucleolin
knockdown blocked HB-19-induced SRC and ERK1/2 in-
activation (Figure 6 last two columns). In Figure 5B and 6
the reduction of HSC70 levels in siRNA transfected cells
does not indicate secondary inhibitory effects of our
siRNA on the expression of cellular proteins. We used
HSC70 for western blot normalization and its reduced
levels are a consequence of the reduced number of cellsdue to the inhibitory effect of NCL knock-down on cell
proliferation. Taken together, these results indicate that
the complex ΗΒ-19/nucleolin interaction triggers a signal
transduction pathway that reduces the phosphorylation
levels of these signal transduction molecules, and also that
it inhibits cellular adhesion and proliferation. Down regu-
lation of mRNA of NCL using siRNA is reported to re-
duce surface nucleolin [8]. Additionally, the expression of
nucleolin on the surface of endothelial cells is due to the
constant induction of nucleolin mRNA, as NCL mRNA
and cell-surface-NCL have half-life time of about 45’-90’
whereas nuclear NCL has more than 24h [7]. Therefore,
although we did not distinguish between surface and
nuclear nucleolin, we can presume with relative safety that
cell surface NCL levels were reduced in our experimental
conditions. Consequently, we can hypothesize the involve-
ment of surface NCL in HB-19 action and consider NCL
to be the main molecule through which HB-19 exerts its
action, knowing that there is more research to be done in
order to extrapolate that the mechanism by which HB-19
exerts its action is through surface NCL.
In summary, in this study we shed light on the role of
cell surface nucleoproteins in the regulation of their
binding proteins signalling and activity in HUVECs.
These results indicate that HB-19 and other pseudopep-
tides like NUCANT 6L could constitute an interesting
tool for inhibiting angiogenesis. This possibility is rein-
forced by the fact that these multimeric pseudopeptides
are synthetic molecules which lack in tissular toxicity
and whose production can be easily upscaled and stable
in serum, thus providing novel therapeutic opportunities
in proliferative diseases.Additional file
Additional file 1: HB-19 inhibits in vitro wound healing of HUVECs.
The scratched areas were quantified in three random fields in each
treatment, and data were calculated from three independent
experiments. Results are expressed as % change relative to control and
are mean values ± SE from at least 3 independent experiments.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
All authors participated in the design of the study. BC performed all
experiments, performed the statistical analysis and drafted the manuscript.
BJP constructed and provided the peptides. CJ helped to draft the
manuscript. KP conceived of the study, participated in its design and
coordination and helped to draft the manuscript. All authors read and
approved the final manuscript.Acknowledgments
We gratefully thank Dr. Mavrommati Evangelia for providing us with
umbilical cords for HUVECs isolation.
Birmpas et al. Vascular Cell 2012, 4:21 Page 10 of 11
http://www.vascularcell.com/content/4/1/21Author details
1Department of Biology, University of Patras, Patras, Greece. 2CNRS, Institut
de Biologie Moléculaire et Cellulaire, Strasbourg, France. 3CNRS, Université
Paris Est Créteil, Créteil Cedex, France.
Received: 24 July 2012 Accepted: 30 November 2012
Published: 24 December 2012
References
1. Srivastava M, Pollard HB: Molecular dissection of nucleolin’s role in growth
and cell proliferation: new insights. FASEB J 1999, 13:1911–1922.
2. Storck S, Shukla M, Dimitrov S, Bouvet P: Functions of the histone
chaperone nucleolin in diseases. Subcell Biochem 2007, 41:125–144.
3. Hovanessian AG, Puvion-Dutilleul F, Nisole S, Svab J, Perret E, Deng JS, Krust
B: The cell-surface-expressed nucleolin is associated with the actin
cytoskeleton. Exp Cell Res 2000, 261:312–328.
4. Carpentier M, Morelle W, Coddeville B, Pons A, Masson M, Mazurier J,
Legrand D: Nucleolin undergoes partial N- and O-glycosylations in the
extranuclear cell compartment. Biochemisty 2005, 44:5804–5814.
5. Semenkovich CF, Ostlund REJ, Olson MO, Yang JW: A protein partially
expressed on the surface of HepG2 cells that binds lipoproteins
specifically is nucleolin. Biochemistry 1990, 29:9708–9713.
6. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E:
Nucleolin expressed at the cell surface is a marker of endothelial cells in
angiogenic blood vessels. J Cell Biol 2003, 163:871–878.
7. Hovanessian AG, Soundaramourty C, El Khoury D, Nondier I, Svab J, Krust B:
Surface expressed nucleolin is constantly induced in tumor cells to
mediate calcium-dependent ligand internalization. PLoS One 2010,
5:e15787.
8. Huang Y, Shi HHZ, Song X, Yuan S, Luo Y: The angiogenesis function of
nucleolin is mediated by vascular endothelial growth factor and
nonmuscle myosin. Blood 2006, 107:3564–3571.
9. Nisole S, Said EA, Mische C, Prevost MC, Krust B, Bouvet P, Bianco A, Briand
JP, Hovanessian AG: The anti-HIV pentameric pseudopeptide HB-19 binds
the C-terminal end of nucleolin and prevents anchorage of virus
particles in the plasma membrane of target cells. J Biol Chem 2002,
277:20877–20886.
10. Said AE, Krust B, Nisole S, Briand JP, Hovanessian AG: The anti-HIV cytokine
midkine binds the cell-surface-expressed nucleolin as a low affinity
receptor. J Biol Chem 2002, 277:37492–37502.
11. Said EA, Courty J, Svab J, Delbe´ J, Krust B, Hovanessian AG: Pleiotrophin
inhibits HIV infection by binding the cell surface expressed nucleolin.
FEBS J 2005, 272:4646–4659.
12. Legrand D, Vigie K, Said EA, Elass E, Masson M, Slomianny MC, Carpentier M,
Briand JP, Mazurier J, Hovanessian AG: Surface nucleolin participates in
both the binding and endocytosis of lactoferrin in target cells. Eur J
Biochem 2004, 271:303–317.
13. Dumler I, Stepanova V, Jerke U, Mayboroda OA, Vogel F, Bouvet P, Tkachuk
V, Haller H, Gulba DC: Urokinase-induced mitogenesis is mediated by
casein kinase 2 and nucleolin. Curr Biol 1999, 9:1468–1476.
14. Stepanova V, Lebedeva T, Kuo A, Yarovoi S, Tkachuk S, Zaitsev S, Bdeir K,
Dumler I, Marks MS, Parfyonova Y, Tkachuk VA, Higazi AA, Cines DB: Nuclear
translocation of urokinase-type plasminogen activator. Blood 2008,
112:100–110.
15. Kleinman HK, Weeks BS, Cannon FB, Sweeney TM, Sephel GC, Clement B,
Zain M, Olson MO, Jucker M, Burrous BA: Identification of a 110-kDa
nonintegrin cell surface laminin-binding protein which recognizes an A
chain neurite-promoting peptide. Arch Biochem Biophys 1991,
290:320–325.
16. Harms G, Kraft R, Grelle G, Volz B, Dernedde J, Tauber R: Identification of
nucleolin as a new L-selectin ligand. Biochem J 2001, 360:531–538.
17. Larrucea S, Gonza_lez-Rubio C, Cambronero R, Ballou B, Bonay P, Lopez-
Granados E, Bouvet P, Fontán G, Fresno M, López-Trascasa M: Cellular
adhesion mediated by factor J, a complement inhibitor. Evidence for
nucleolin involvement. J Biol Chem 1998, 273:31718–31725.
18. Reyes-Reyes EM, Akiyama SK: Cell-surface nucleolin is a signal transducing
P-selectin binding protein for human colon carcinoma cells. Exp Cell Res
2008, 314:2212–2223.
19. Turck N, Lefebvre O, Gross I, Gendry P, Kedinger M, Simon-Assmann P,
Launay JF: Effect of laminin-1 on intestinal cell differentiation involves
inhibition of nuclear nucleolin. J Cell Physiol 2006, 206:545–555.20. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO: Discovery and
development of the G-rich oligonucleotide AS1411 as a novel treatment
for cancer. Exp Mol Pathol 2009, 86:151–164.
21. Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, Müller JM, Alke A,
Seidl C, Bruchertseifer F, Morgenstern A, Senekowitsch-Schmidtke R, Essler
M: Treatment of peritoneal carcinomatosis by targeted delivery of the
radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of
tumor cells. PLoS One 2009, 4:e5715.
22. Shi H, Huang Y, Zhou H, Song X, Yuan S, Fu Y, Luo Y: Nucleolin is a
receptor that mediates antiangiogenic and antitumor activity of
endostatin. Blood 2007, 110:2899–2906.
23. Fogal V, Sugahara KN, Ruoslahti E, Christian S: Cell surface nucleolin
antagonist causes endothelial cell apoptosis and normalization of tumor
vasculature. Angiogenesis 2009, 12:91–100.
24. Destouches D, El Khoury D, Hamma-Kourbali Y, Krust B, Albanese P, Katsoris
P, Guichard G, Briand JP, Courty J, Hovanessian AG: Suppression of tumor
growth and angiogenesis by a specific antagonist of the cell-surface
expressed nucleolin. PLoS One 2008, 3:e2518.
25. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial
cells derived from umbilical veins. Identification by morphologic and
immunologic criteria. J Clin Invest 1973, 52:2745–2756.
26. Polykratis A, Katsoris P, Courty J, Papadimitriou E: Characterization of
heparin affin regulatory peptide signaling in human endothelial cells.
J Biol Chem 2005, 280:22454–22461.
27. Haas TL: Endothelial cell regulation of matrix metalloproteinases. Can J
Physiol Pharmacol 2005, 83:1–7.
28. Sluijter JP, de Kleijn DP, Pasterkamp G: Vascular remodeling and protease
inhibition–bench to bedside. Cardiovasc Res 2006, 69:595–603.
29. Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis.
Cancer Metastasis Rev 2006, 25:9–34.
30. Cross M, Dixelius J, Matsumoto T, Claesson-Welsh L: VEGF-receptor signal
transduction. Trends Biochem Sci 2003, 28:488–494. Review.
31. Zhao X, Guan JL: Focal adhesion kinase and its signaling pathways in cell
migration and angiogenesis. Adv Drug Deliv Rev 2011, 63:610–615.
32. Nisole S, Krust B, Callebaut C, Guichard G, Muller S, Briand JP, Hovanessian
AG: The anti-HIV pseudopeptide HB-19 forms a complex with the cell-
surface-expressed nucleolin independent of heparan sulfate
proteoglycans. J Biol Chem 1999, 274:27875–27884.
33. Krust B, El Khoury D, Nondier I, Soundaramourty C, Hovanessian AG:
Targeting surface nucleolin with multivalent HB-19 and related Nucant
pseudopeptides results in distinct inhibitory mechanisms depending on
the malignant tumor cell type. BMC Cancer 2011, 11:333.
34. Nisole S, Krust B, Hovanessian AG: Anchorage of HIV on permissive cells
leads to co-aggregation of viral particles with surface nucleolin at
membrane raft microdomains. Exp Cell Res 2002, 276:155–173.
35. Losfeld ME, Leroy A, Coddeville B, Carpentier M, Mazurier J, Legrand D: N-
Glycosylation influences the structure and self-association abilities of
recombinant nucleolin. FEBS J 2011, 278:2552–2564.
36. Ghisolfi L, Joseph G, Amalric F, Erard M: The glycine-rich domain of
nucleolin has an unusual supersecondary structure responsible for
its RNAHelix- destabilizing properties. J Biol Chem 1992,
267:2955–2959.
37. Ghisolfi-Nieto L, Joseph G, Puvion-Dutilleul F, Amalric F, Bouvet P: Nucleolin
is a sequence-specific RNA-binding protein: characterization of targets
on pre-ribosomal RNA. J Mol Biol 1996, 260:34–53.
38. Hanakahi LA, Sun H, Maizels N: High affinity interactions of nucleolin with
G-G-paired rDNA. J Biol Chem 1999, 274:15908–15912.
39. Bouvet P, Diaz J-J, Kindbeiter K, Madjar J-J, Amalric F: Nucleolin interacts
with several ribosomal proteins through its RGG domain. J Biol Chem
1998, 273:19025–19029.
40. Pluddemann A, Neyen C, Gordon S: Macrophage scavenger receptor and
host-derived ligands. Methods 2007, 43:207–217.
41. El Khoury D, Destouches D, Lengagne R, Krust B, Hamma-Kourbali Y,
Garcette M, Niro S, Kato M, Briand JP, Courty J, Hovanessian AG, Prévost-
Blondel A: Targeting surface nucleolin with a multivalent pseudopeptide
delays development of spontaneous melanoma in RET transgenic mice.
BMC Cancer 2012, 24:325.
42. Krust B, El Khoury D, Soundaramourty C, Nondier I, Hovanessian AG:
Suppression of tumorigenicity of rhabdoid tumor derived G401 cells by
the multivalent HB-19 pseudopeptide that targets surface nucleolin.
Biochimie 2011, 93:426–433.
Birmpas et al. Vascular Cell 2012, 4:21 Page 11 of 11
http://www.vascularcell.com/content/4/1/2143. Callebaut C, Blanco J, Benkirane N, Krust B, Jacotot E, Guichard G, Seddiki N,
Svab J, Dam E, Muller S, Briand JP, Hovanessian AG: Identification of V3
loop-binding proteins as potential receptors implicated in the binding of
HIV particles to CD4+ cells. J Biol Chem 1998, 273:21988–21997.
44. Sinclair JF, O’Brien AD: Cell surface-localized nucleolin is a eukaryotic
receptor for the adhesin intimin-gamma of enterohemorrhagic
Escherichia coli O157:H7. J Biol Chem 2002, 277:2876–2885.
45. Losfeld ME, Khoury DE, Mariot P, Carpentier M, Krust B, Briand JP, Mazurier J,
Hovanessian AG, Legrand D: The cell surface expressed nucleolin is a
glycoprotein that triggers calcium entry into mammalian cells. Exp Cell
Res 2009, 315:357–369.
46. Jordon G: At the heart of the nucleolus. Nature 1987, 329:489–490.
47. Herrera AH, Olson MOJ: Association of protein C23 with rapidly labeled
nucleolar RNA. Biochemistry 1986, 25:6258–6264.
48. Borer RA, Lehner CF, Eppenberger HM, Nigg EA: Major nucleolar proteins
shuttle between nucleus and cytoplasm. Cell 1989, 56:379–390.
49. Bouche G, Gas N, Prats H, Baldin V, Tauber JP, Teissie J, Amalric F: Basic
fibroblast growth factor enters the nucleolus and stimulates the
transcription of ribosomal genes in ABAE cells undergoing Go-G1
transition. Proc Natl Acad Sci USA 1987, 84:6770–6774.
50. Caizergues-Ferrer M, Mariottini P, Curie C, Lapeyre B, Gas N, Amalric F,
Amaldi F: Nucleolin from Xenopus laevis: cDNA cloning and expression
during development. Genes Dev 1989, 3:324–333.
51. Erard M, Lakhdar-Ghazal F, Amalric F: Repeat peptide motifs which contain
beta-turns and modulate DNA condensation into chromatin. Eur J
Biochem 1990, 191:19–26.
52. Hanakahi LA, Dempsey LA, Li MJ, Maizels N: Nucleolin is one component
of the B-cell specific transcription factor and switch region binding
protein, LR1. Proc NatI Acad Sci USA 1997, 94:3605–3610.
53. Borggrefe T, WabI M, Akhmedov AT, Jessberger R: A B-cell-specific DNA
recombination complex. J Biol Chem 1998, 273:17025–17035.
54. Minota S, Jarjour WN, Suzuki N, Nojima Y, Roubey RA, Mimura T, Yamada A,
Hosoya T, Takaku F, Winfield JB: Autoantibodies to nucleolin in systemic
lupus erythematosus and other diseases. J Immunol 1991, 146:2249–2252.
55. Valdez BC, Henning D, Busch RK, Srivastava M, Busch H: Immunodominant
RNA recognition motifs of human nucleolin/C23. Mol Immunol 1995,
32:1207–1213.
56. Tuteja N, Huang NW, Skopac D, Tuteja R, Hrvatic S, Zhang J, Ponger S, Joself
G, Faucher C, Amalric F: Human DNA helicase IV is nucleolin, an RNA
helicase modulated by phosphorylation. Gene 1995, 160:143–148.
57. Tuteja N, Phan TN, Tuteja R, Ochem A, Falaschi A: Inhibition of DNA
unwinding and ATPase activities of human DNA helicase II by
chemotherapeutic agents. Biochem Biophys Res Commun 1997,
236:636–640.
58. Yang TH, Tsai WH, Lei HY, Lai MY, Chen DS, Yeh NH, Lee SC: Purification
and characterization of nucleolin and its identification as a transcription
repressor. Mol Cell Biol 1994, 14:6068–6074.
59. Ugrinova I, Monier K, Ivaldi C, Thiry M, Storck S, Mongelard F, Bouvet P:
Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest
and defects in centrosome duplication. BMC Mol Biol 2007, 8:66.
60. Gorsler T, Murzik U, Ulbricht T, Hentschel J, Hemmerich P, Melle C: DNA
damage-induced translocation of S100A11 into the nucleus regulates
cell proliferation. BMC Cell Biol 2010, 11:100.
doi:10.1186/2045-824X-4-21
Cite this article as: Birmpas et al.: The pseudopeptide HB-19 binds to
cell surface nucleolin and inhibits angiogenesis. Vascular Cell 2012 4:21.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
